Humanized CD19-directed CAR-T Cell Therapy in Pediatric Relapsed/Refractory Acute Lymphoblastic Leukemia With CNSL or Neurological Comorbidity

Chimeric antigen receptor T cell (CAR-T) therapy has breakthrough potential for relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL). However, because of the risk for neurotoxicity, trials usually exclude patients with central nervous system leukemia (CNSL) or active neurological comorbiditi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Na, Shao, Jingbo, Li, Hong, Zhu, Jiashi, Xia, Min, Chen, Kai, Jiang, Hui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Clinical Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528944/
https://www.ncbi.nlm.nih.gov/pubmed/36018262
http://dx.doi.org/10.1097/CJI.0000000000000437

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9528944/
https://www.ncbi.nlm.nih.gov/pubmed/36018262
http://dx.doi.org/10.1097/CJI.0000000000000437

Ejemplares similares